Insulin Tregopil: An Ultra-Fast Oral Recombinant Human Insulin Analog: Preclinical and Clinical Development in Diabetes Mellitus.

Abstract in brief

• Insulin Tregopil is an ultra-fast oral insulin analog designed to improve glycemic control in diabetes patients, potentially reducing issues like injection discomfort and hypoglycemia associated with traditional insulin therapy.
• It mimics natural insulin secretion by being absorbed through the gastrointestinal tract, leading to better post-meal blood sugar management, especially when compared to placebo and traditional insulins like insulin aspart in clinical trials.
• The formulation involves a recombinant insulin modified with a special polyethylene glycol compound and an absorption enhancer called sodium caprate, and it has demonstrated a good safety profile with fewer adverse effects in clinical studies.]